Transcatheter aortic valve replacement (TAVR) with the Evolut self-expanding valve was non-inferior to surgery in patients with low surgical risk. After two years, the primary endpoint of death or disabling stroke was similar between both strategies. This presentation at EuroPCR 2021 reinforces the results presented during the American College of Cardiology (ACC) 2019 Congress and…
EuroPCR 2021 | TVT Registry: Outcomes of TAVR in Low Surgical Risk Bicuspids
In bicuspid patients with aortic stenosis and low surgical risk, transcatheter aortic valve replacement (TAVR) with balloon expandable valve offers results comparable to normal anatomy results. These data come from the TVT registry, presented at EuroPCR 2021 scientific sessions. Stroke and death rates (inhospital, 30 days and one year) in bicuspid patients did not result…
EuroPCR 2021 | CLASP: 2 Year Outcomes of the New Mitral Valve Repair System
The 2-year outcomes of the transcatheter mitral valve repair system PASCAL have shown high survival and low rehospitalization rates, and durable reduction of mitral valve regurgitation. These results were provided by the CLASP trial, presented during the EuroPCR scientific sessions and simultaneously published in JACC: Cardiovascular Interventions. The PASCAL system (Edwards) has been authorized for…